Bone density and bone turnover marker monitoring after discontinuation of alendronate therapy: an evidence-based decision to do less

JAMA Intern Med. 2014 Jul;174(7):1134-5. doi: 10.1001/jamainternmed.2014.162.

Authors

Margaret L Gourlay¹, Kristine E Ensrud²

Affiliations

¹ Department of Family Medicine, University of North Carolina, Chapel Hill.
² Department of Medicine, University of Minnesota Medical School, Minneapolis3Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis4Department of Medicine, Minneapolis VA Health Care System, Minneapolis.

PMID: 24798510
DOI: 10.1001/jamainternmed.2014.162

No abstract available

Publication types

Comment

MeSH terms

Alendronate / administration & dosage*
Alkaline Phosphatase / blood*
Bone Density Conservation Agents / administration & dosage*
Female
Forecasting*
Fractures, Bone / prevention & control*
Humans

Substances

Bone Density Conservation Agents
Alkaline Phosphatase
Alendronate